GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Shiller PE Ratio

Chong Kun Dang Pharmaceutical (XKRX:185750) Shiller PE Ratio : 14.25 (As of May. 12, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Shiller PE Ratio?

As of today (2025-05-12), Chong Kun Dang Pharmaceutical's current share price is ₩79300.00. Chong Kun Dang Pharmaceutical's E10 for the quarter that ended in Dec. 2024 was ₩5,563.85. Chong Kun Dang Pharmaceutical's Shiller PE Ratio for today is 14.25.

The historical rank and industry rank for Chong Kun Dang Pharmaceutical's Shiller PE Ratio or its related term are showing as below:

XKRX:185750' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.8   Med: 19.2   Max: 27.69
Current: 14.25

During the past years, Chong Kun Dang Pharmaceutical's highest Shiller PE Ratio was 27.69. The lowest was 13.80. And the median was 19.20.

XKRX:185750's Shiller PE Ratio is ranked better than
77.67% of 524 companies
in the Drug Manufacturers industry
Industry Median: 24.53 vs XKRX:185750: 14.25

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Chong Kun Dang Pharmaceutical's adjusted earnings per share data for the three months ended in Dec. 2024 was ₩652.095. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ₩5,563.85 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Chong Kun Dang Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Shiller PE Ratio Chart

Chong Kun Dang Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 25.19 16.00

Chong Kun Dang Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.19 20.58 17.28 19.40 16.00

Competitive Comparison of Chong Kun Dang Pharmaceutical's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Chong Kun Dang Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chong Kun Dang Pharmaceutical's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chong Kun Dang Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chong Kun Dang Pharmaceutical's Shiller PE Ratio falls into.


;
;

Chong Kun Dang Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chong Kun Dang Pharmaceutical's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=79300.00/5563.85
=14.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chong Kun Dang Pharmaceutical's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Chong Kun Dang Pharmaceutical's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=652.095/121.1352*121.1352
=652.095

Current CPI (Dec. 2024) = 121.1352.

Chong Kun Dang Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 439.946 99.721 534.422
201506 -1,901.242 100.051 -2,301.906
201509 603.064 100.111 729.714
201512 370.908 100.220 448.312
201603 400.012 100.561 481.853
201606 525.904 100.791 632.057
201609 1,072.790 101.461 1,280.811
201612 947.575 101.561 1,130.201
201703 783.780 102.851 923.119
201706 769.566 102.611 908.492
201709 1,135.736 103.491 1,329.374
201712 999.015 102.991 1,175.016
201803 195.437 104.101 227.417
201806 875.559 104.130 1,018.541
201809 935.257 105.651 1,072.333
201812 1,062.895 104.351 1,233.859
201903 748.454 104.491 867.675
201906 873.072 104.881 1,008.380
201909 1,000.675 105.200 1,152.249
201912 1,278.192 105.121 1,472.908
202003 1,234.837 105.354 1,419.803
202006 1,907.886 105.112 2,198.727
202009 2,412.477 106.198 2,751.813
202012 1,082.363 105.765 1,239.652
202103 1,040.719 107.357 1,174.283
202106 1,660.214 107.579 1,869.427
202109 148.909 108.759 165.854
202112 261.167 109.676 288.453
202203 1,222.330 111.848 1,323.825
202206 1,629.198 114.072 1,730.071
202209 2,012.742 114.715 2,125.383
202212 852.349 115.179 896.425
202303 2,550.567 116.507 2,651.878
202306 3,048.526 117.182 3,151.367
202309 3,248.980 118.964 3,308.288
202312 5,631.293 118.837 5,740.192
202403 1,917.143 120.123 1,933.294
202406 4,007.619 120.007 4,045.285
202409 1,643.810 120.861 1,647.537
202412 652.095 121.135 652.095

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chong Kun Dang Pharmaceutical  (XKRX:185750) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Chong Kun Dang Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chong Kun Dang Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical Headlines

No Headlines